Schizophrenia, Tardive Dyskinesia, and the Abnormal Involuntary Movement Scale (AIMS)

2002 ◽  
Vol 8 (2) ◽  
pp. 51-56 ◽  
Author(s):  
Victoria Menzies ◽  
Sarah P. Farrell
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

2005 ◽  
Vol 77 (2-3) ◽  
pp. 119-128 ◽  
Author(s):  
Georges M. Gharabawi ◽  
Cynthia A. Bossie ◽  
Robert A. Lasser ◽  
Ibrahim Turkoz ◽  
Stephen Rodriguez ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Rating Scale ◽  
Extrapyramidal Symptom ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale ◽  
Symptom Rating

Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia

2020 ◽  
Vol 40 (4) ◽  
pp. 373-380 ◽  
Author(s):  
Stanley N. Caroff ◽  
Shirley H. Leong ◽  
Christopher B. Roberts ◽  
Rosalind M. Berkowitz ◽  
E. Cabrina Campbell
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

Orofacial Dyskinesia, Cognitive Function and Medication

1986 ◽  
Vol 149 (2) ◽  
pp. 216-220 ◽  
Author(s):  
Philip Thomas ◽  
Ralph McGuire
Keyword(s):  
Regression Analysis ◽  
Cognitive Function ◽  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
The Other ◽  
Orofacial Dyskinesia ◽  
Duration Of Treatment ◽  
Delayed Recall ◽  
Abnormal Involuntary Movement Scale ◽  
Abnormal Movements

The presence of tardive dyskinesia in a sample of 43 patients with schizophrenia and 37 psychopaths who had been hospitalised for many years and exposed to large amounts of medication was assessed while testing their cognitive function. Subjects who showed no evidence of abnormal movements performed significantly better on the test of delayed recall, but there were no differences in performance on any of the other tests of cognitive function used. Multiple regression analysis revealed that age and the total lifetime dose of neuroleptic medication received (in chlorpromazine equivalents) were the only variables to predict the Abnormal Involuntary Movement Scale score, although a large amount of variance in this variable was unaccounted for. The duration of treatment with neuroleptics did not predict AIMS score.

scholarly journals Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 152-152
Author(s):  
Leslie Citrome ◽  
Leslie Lundt ◽  
Chirag Shah ◽  
Tara Carmack
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Real Life ◽  
Meaningful Improvement ◽  
Once Daily ◽  
Abnormal Involuntary Movement Scale ◽  
Clinical Measure ◽  
Long Term Study ◽  
Using Data ◽  
Post Hoc

AbstractObjectiveThe Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1–7) is usually the primary efficacy measure in tardive dyskinesia (TD) clinical trials. However, item 8 of the AIMS (clinician’s global impression of severity) might also be an appropriate assessment in real-life healthcare settings. To explore the potential of item 8 as a clinical measure, post hoc analyses were conducted using data from a long-term study of valbenazine, an approved TD medication.MethodsIn KINECT 4 (NCT02405091), adults with TD received once-daily valbenazine (40 or 80 mg) for 48 weeks. Analyses included two sets of AIMS item 8 scores: based on investigators ratings of item 8 using protocol-defined descriptors; and based on investigators highest scores from items 1–7 (analyzed post hoc). Shift analyses included an improvement from score =3 at baseline (moderate or severe) to score =2 at Week 48 (none to mild).ResultsAt baseline in all participants (N=163), AIMS item 8 mean scores were 3.2 (protocol) and 3.3 (post hoc). In participants with a score =3 at baseline per investigators ratings using protocol-defined descriptors, 95.9% [94/98] shifted to a score =2 by Week 48. A similar result (93.9% [93/99]) was found when item 8 was based on investigators highest scores from items 1–7.ConclusionShift analyses using AIMS item 8 scores indicated that most participants in KINECT 4 had a clinically meaningful improvement after 48 weeks of once-daily treatment with valbenazine. AIMS item 8 may be an appropriate clinical measure for assessing changes in TD severity.FundingNeurocrine Biosciences, Inc.

Assessment of Tardive Dyskinesia Using the Abnormal Involuntary Movement Scale

1985 ◽  
Vol 173 (6) ◽  
pp. 353-357 ◽  
Author(s):  
RICHARD D. LANE ◽  
WILLIAM M. GLAZER ◽  
THOMAS E. HANSEN ◽  
WILLIAM H. BERMAN ◽  
STEPHEN I. KRAMER
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

scholarly journals Improvement of Tardive Dyskinesia during Mindfulness Meditation

2021 ◽  
Vol 13 (3) ◽  
pp. 439-444
Author(s):  
Maria Angela Santoro ◽  
Isolde English ◽  
Idil Sezer ◽  
Mickael Amagat ◽  
Frank Ly ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Cognitive Therapy ◽  
Stress Reduction ◽  
Therapeutic Approach ◽  
First Generation ◽  
Mindfulness Meditation ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale ◽  
Mindfulness Based Stress Reduction

Background: We report the case of a patient presenting with orofacial tardive dyskinesia (TD), following administration of a first-generation antipsychotic (Loxapine). Intervention: Four weeks of repeated sessions of mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) protocols were administered, with TD hetero-quantified before and during each session via the Abnormal Involuntary Movement Scale (AIMS). Results: The dyskinesia ameliorated quantitatively and qualitatively (1) during each session, and (2) at resting conditions in the long term. During some sessions, after which patients’ compliance was auto-evaluated as maximal, complete arrest of the TD was observed. Hypothesis and Conclusion: We suggest mindfulness meditation as a novel adjunctive therapeutic approach for tardive dyskinesia, and invite for further clinical and neurological investigations.

The Course of Tardive Dyskinesia in Patients on Long-Term Neuroleptics

1989 ◽  
Vol 154 (4) ◽  
pp. 523-528 ◽  
Author(s):  
J. A. Bergen ◽  
E. A. Eyland ◽  
J. A. Campbell ◽  
P. Jenkings ◽  
K. Kellehear ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Psychiatric Patients ◽  
Involuntary Movement ◽  
Neuroleptic Treatment ◽  
Community Based ◽  
Abnormal Involuntary Movement Scale ◽  
History Of ◽  
Significant Change ◽  
Chronic Psychiatric Patients

Results are presented of five consecutive annual examinations using the Abnormal Involuntary Movement Scale for 101 community-based chronic psychiatric patients. These 101 patients had a history of longer and more consistent neuroleptic treatment than the 231 patients who initially entered the study, so no conclusions about prevalence of TD can be drawn. At each examination two-thirds of this group showed signs of TD; however, only 45% were TD positive at most examinations and 24% were best described as having fluctuating TD status. Of those patients who were consistently TD positive, 82% showed no overall significant change in summed AIMS scores, 11% improved and 7% became worse.

Tardive Dyskinesia: Fluctuating Patient or Fluctuating Rater

1984 ◽  
Vol 144 (5) ◽  
pp. 498-502 ◽  
Author(s):  
J. A. Bergen ◽  
D. A. Griffiths ◽  
J. E. Rey ◽  
P. J. V. Beumont
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Clinical Manifestations ◽  
Unexpected Finding ◽  
Abnormal Involuntary Movement Scale ◽  
Rater Variability

SummaryTardive dyskinesia (TD) is usually described as fluctuating in its clinical manifestations. We attempted to quantify fluctuations in TD using the Abnormal Involuntary Movement Scale (AIMS). Three psychiatrists rated multiple video-recorded examinations of four outpatients with mild TD. The unexpected finding was that within-rater variability dominated within-patient variability.

Sign in / Sign up

Export Citation Format

Share Document